Mr. Mamtani has been one of the leading voices on the Street in prophylactic innovations for cardiovascular and infectious diseases, both aimed at reducing significant burden on global healthcare systems. Individually, was ranked within 1% among thousands of …

Jan 8, 2025 · Mayank Mamtani is a Wall Street analyst working for B. Riley Securities. Mayank has covered 32 stocks with a 43.27% success rate and an average return of 36.35%.

May 6, 2024 · Mayank Mamtani has given his Buy rating due to a combination of factors, including the strength of recent clinical trial results for Lineage Cell Therapeutics.

Jul 28, 2020 · Mayank Mamtani was promoted to Senior Analyst and Group Head of Healthcare Research. He joined B. Riley as a Research Analyst in 2018 and covers biotechnology companies pioneering cutting-edge therapeutics innovation in liver diseases, hematology-oncology, and infectious diseases.

Aug 28, 2024 · Analyst Mayank Mamtani of B.Riley Financial reiterated a Buy rating on Harrow Health (HROW – Research Report), retaining the price target of $50.00. Mayank Mamtani has given his Buy rating due...

Aug 5, 2024 · Mayank Mamtani has given his Buy rating due to a combination of factors including the strategic termination of a licensing deal with Biogen and the progression of Denali Therapeutics’ Enzyme...

Mayank Mamtani B Riley FBR . Madrigal’s ambitious research programs led to the first FDA-approved treatment in NASH. Learn More. Madrigal Pharmaceuticals. 200 Barr Harbor Drive, Suite 200. West Conshohocken, Pennsylvania 19428. About Us; Our Programs; NASH; Investors & Media; Careers; Contact;

Sep 29, 2012 · Analyst-Equity at B. Riley Securities, Inc., Discover Mayank Mamtani's known position history, network and 96 relationships. Find out about his known public assets.

Feb 1, 2021 · Diversifying a portfolio is often cited as a safe investing strategy, but it is also the game plan adopted by Sorrento Therapeutics (SRNE). This varied approach could provide investors with some...